Ijeoma Umelo Amir Noeparast Gang Chen Marleen Renard Caroline Geers Johan Vansteenkiste Philippe Giron Olivier De Wever Erik Teugels Jacques De Grève
10.18632/oncotarget.6585
Oncotarget
2016 Jan 19;7(3):3068-83.
her inhibitor her3 kinase mutation her3-v855a lung cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/26689995/
Antineoplastic Agents / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Erlotinib Hydrochloride / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / genetics Protein Kinase Inhibitors / therapeutic use Receptor, ErbB-3 / genetics
Antineoplastic Agents / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Erlotinib Hydrochloride / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / genetics Protein Kinase Inhibitors / therapeutic use Receptor, ErbB-3 / genetics Case Reports Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't Adolescent Amino Acid Sequence Brain Neoplasms / secondary Carcinoma, Non-Small-Cell Lung / secondary Cell Line, Tumor Crystallography, X-Ray ErbB Receptors / genetics Genetic Predisposition to Disease Humans Lung Neoplasms / pathology Male Molecular Sequence Data Mutation / genetics Neuregulin-1 / metabolism Phosphorylation Prospective Studies Protein Structure, Tertiary Receptor, ErbB-2 / metabolism Receptor, ErbB-3 / metabolism Tomography, X-Ray Computed Antineoplastic Agents Neuregulin-1 Protein Kinase Inhibitors neuregulin beta Erlotinib Hydrochloride EGFR protein, human ERBB2 protein, human ERBB3 protein, human ErbB Receptors Receptor, ErbB-2 Receptor, ErbB-3
PMC4823091
26689995
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
2016